AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23176986
Drug: morphine 100
RxNorm normalized name: MORPHINE 100MG/NALTREXONE 4MG SA CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine 100 μg
Trial: 23176986
Drug: clonidine 75
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clonidine 75 μg
Trial: 18720713
Drug: Antidepressant coaxil
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant coaxil during perioperative period (6 weeks)
Trial: 18720713
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no coaxil treatment)
Trial: 16505759
Drug: Repeated large
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated large volume paracentesis plus intravenous albumin (group 1)
Trial: 16505759
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clonidine (0.075 mg twice daily) and spironolactone (200 to 400 mg daily) (group 2)
Trial: 16505759
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of clonidine and spironolactone (group 2)
Trial: 15198841
Drug: Weekly fructosamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly fructosamine testing (Group 1)
Trial: 12450445
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care of daily glucose (Group 2)
Trial: 7795502
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose alcohol (80 mg/100 ml)
Trial: 7795502
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose alcohol (40 mg/100 ml)
Trial: 7795502
Drug: Expecting alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Expecting alcohol with high dose alcohol
Trial: 7025168
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg body weight as a single dose
Trial: 7025168
Drug: 40 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/kg as a single dose
Trial: 7025168
Drug: 25 mg/kg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/kg, twice a day at a 6-hour interval
Trial: 26243373
Drug: Anti-tuberculosis therapy
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-tuberculosis therapy plus Silybum marianum capsule
Trial: 26243373
Drug: Anti-tuberculosis therapy
RxNorm normalized name: Mycobacterium tuberculosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-tuberculosis therapy plus vitamin C tablet
Trial: 24576517
Drug: Extended administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extended administration of oral betrixaban (35‐42 days)
Trial: 24576517
Drug: Standard short
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard short course of prophylaxis with subcutaneous enoxaparin (10 ± 4 days followed by placebo)
Trial: 22510506
Drug: Feiji Decoction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feiji Decoction for soothing the liver combined with psychotherapy and chemotherapy
Trial: 18400357
Drug: Raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 60 mg/day (RG)
Trial: 10575655
Drug: Etomoxir (ETO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomoxir (ETO) 75 mg
Trial: 10575655
Drug: Etomoxir (ETO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomoxir (ETO) 150 mg
Trial: 8688226
Drug: Concurrent external
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent external radiation therapy (70 Gy/39 fractions/8 weeks) and chemotherapy with cisplatin (50 mg/m2 in short infusion, D1, D15, D29, D43) and fluorouracil (5 mg/kg, intra-muscular, every Monday, Wednesday and Friday)
Trial: 8688226
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (non responders to induction chemotherapy)
Trial: 8688226
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (non responders to induction chemotherapy)
Trial: 8688226
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (responders to induction chemotherapy)
Trial: 8688226
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (responders to induction chemotherapy)
Trial: 1770421
Drug: Group 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: Dentifrice with 0.075% sanguinaria extract and 2.0% zinc chloride, plus oral rinse with 0.03% sanguinaria extract and 0.2% zinc chloride.
Trial: 1770421
Drug: Group 3:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 3: Dentifrice with 0.8% sodium monofluorophosphate, 0.075% sanguinaria extract, and 0.05% zinc chloride, plus oral rinse with 0.03% sanguinaria extract and 0.2% zinc chloride.
Trial: 15808922
Drug: Intravenous (iv)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (iv) ghrelin administration (1.0 microg/kg) in bulimia nervosa (BW)
Trial: 15808922
Drug: Intravenous (iv)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (iv) ghrelin administration (1.0 microg/kg) in healthy women (HW)
Trial: 2254718
Drug: Normal milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal milk (1180 mg Ca2+, 1650 mg K+, 110 mg Mg2+ d‐1)
Trial: 2254718
Drug: Mineral-poor milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineral-poor milk (95 mg Ca2+, 580 mg K+, 10 mg Mg2+ d‐1)
Trial: 27750388
Drug: Commercial phage
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial phage preparation (Coliproteus from Microgen/Russia)
Trial: 27750388
Drug: Coliphage preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coliphage preparations or placebo
Trial: 21786113
Drug: Silymarin-based cream
RxNorm normalized name: silymarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silymarin-based cream (Leviaderm(®))
Trial: 17588273
Drug: Manual-controlled infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manual-controlled infusion of propofol
Trial: 11229823
Drug: Antithrombin III
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombin III supplementation (50 U/kg) by intravenous infusion prior to incision
Trial: 9893913
Drug: Nefopam (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam (0.15 mg/kg)
Trial: 2691569
Drug: rIFN‐alpha 2c,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIFN‐alpha 2c, 10 MU/m2 body surface, twice weekly, intramuscularly for 6 months
Trial: 1090684
Drug: 2% micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% micronized griseofulvin applied 3 times daily for 3 weeks
Trial: 28549145
Drug: High-dose rVSVΔG‐ZEBOV‐GP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rVSVΔG‐ZEBOV‐GP (1 × 10^8 pfu, n = 264)
Trial: 21550589
Drug: Cognitive-behaviour therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behaviour therapy (CBT) consisting of 6 sessions combining behavioural sleep medicine techniques and anxiety treatment techniques
Trial: 19687350
Drug: Amlodipine/benazepril (5.0/20.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine/benazepril (5.0/20.0 mg, 5.0/40.0 mg, 10.0/40.0 mg)
Trial: 19687350
Drug: Hydrochlorothiazide/benazepril (12.5/20.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide/benazepril (12.5/20.0 mg, 12.5/40.0 mg, 25.0/40.0 mg)
Trial: 16971360
Drug: Tazarotene plus
RxNorm normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tazarotene plus hydroquinone (4% cream)
Trial: 16971360
Drug: Tazarotene alone
RxNorm normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tazarotene alone (0.1% cream)
Trial: 14755009
Drug: Consolidation/maintenance therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation/maintenance therapy
Trial: 8325766
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of the first seizure
Trial: 8325766
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of recurrences
Trial: 28871492
Drug: Antibiotics +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics + Probiotics (Lactobacillus rhamnosus GG)
Trial: 28871492
Drug: Only Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only Antibiotics
Trial: 28871492
Drug: Antibiotics +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics + Placebo (glucose solution at 5%)
Trial: 28361113
Drug: Standard bodyweight-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard bodyweight-based tacrolimus starting dose
Trial: 28361113
Drug: CYP3A5 genotype-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYP3A5 genotype-based tacrolimus starting dose
Trial: 26653236
Drug: Internal medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internal medicine (control)
Trial: 20925972
Drug: Sequential low-frequency
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential low-frequency right-sided followed by high-frequency left-sided rTMS
Trial: 20925972
Drug: Sequential low-frequency
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential low-frequency rTMS to both hemispheres
Trial: 16598468
Drug: Mitomycin C
RxNorm normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mitomycin C (0.05 mg/ml) applied topically to the filtering bleb for 5 min on the 3 days after surgery
Trial: 2866932
Drug: Amiloride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride (5 mg) with Hydrochlorothiazide (50 mg)
Trial: 2866932
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (Atenolol + Amiloride + Hydrochlorothiazide)
Trial: 2866932
Drug: Diuretic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic treatment alone or in combination
Trial: 30347072
Drug: SDD (mouthpaste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SDD (mouthpaste and gastrointestinal suspension with the same antibiotics)
Trial: 20146685
Drug: Percutaneous coronary
RxNorm normalized name: Glebionis coronaria whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Percutaneous coronary interventions (PCI) with drug eluting stents (DES)
Trial: 1994402
Drug: High-dose urokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose urokinase (250,000 U/h for 4 hours and then 125,000 U/h)
Trial: 1994402
Drug: Low-dose urokinase
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose urokinase (50,000 U/h)
Trial: 1994402
Drug: High-dose urokinase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose urokinase
Trial: 1994402
Drug: Low-dose urokinase
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose urokinase
Trial: 25828951
Drug: Three narrow
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three narrow diameter implants placed using osteotomes with a one-stage procedure and 12-week loading.
Trial: 20106646
Drug: EPA/DHA (3.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA/DHA (3.4 g/d)
Trial: 17295758
Drug: Prokinetic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prokinetic agents (metoclopramide, domperidone, trimebutine, cisapride, itopride, mosapride)
Trial: 16086935
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (400 IU) and Vitamin C (1000 mg) daily
Trial: 16086935
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (1000 mg) only
Trial: 12065207
Drug: High-dose candesartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose candesartan (16 mg)
Trial: 12065207
Drug: Low-dose candesartan
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose candesartan (8 mg)
Trial: 12065207
Drug: Standardised medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised medication
Trial: 10049410
Drug: Endoscope insertion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscope insertion by oral route
Trial: 8786163
Drug: Phyllanthus amarus
RxNorm normalized name: Phyllanthus amarus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phyllanthus amarus preparation for 10 days
Trial: 28276566
Drug: Warfarin (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (high risk)
Trial: 25964594
Drug: 3D conformal
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3D conformal radiotherapy (3DCRT) with hormonal therapy (HT) administered in 92% of patients
Trial: 10581657
Drug: FP 4
RxNorm normalized name: PEANUT ALLERGEN-DNFP 40MG (LEVEL 5) POWDER,ORAL,PKT,30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP 4 mg
Trial: 10581657
Drug: FP 1
RxNorm normalized name: Peanut Allergen-dnfp 1 MG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FP 1 mg
Trial: 8694380
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (nitrous oxide and oxygen administered)
Trial: 1812903
Drug: 0.2% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% chlorhexidine solution (1 mL) irrigation
Trial: 6682323
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg carteolol p.o.
Trial: 6682323
Drug: 1, 2,
RxNorm normalized name: Pneumococcal 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1, 2, 5 or 25 mg carteolol
Trial: 6682323
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg carteolol
Trial: 6682323
Drug: 5 to
RxNorm normalized name: Hy5 Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 to 25 mg carteolol
Trial: 24923300
Drug: WHO Package
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: WHO Package of CV risk assessment, patient education, initiation and titration of antihypertensive medications, behavioral counseling on lifestyle behaviors, and medication adherence every three months for 12 months.
Trial: 15703368
Drug: High-dose oxymorphone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oxymorphone ER (3 x 20 mg q12h) + naltrexone (50 mg q24h)
Trial: 15703368
Drug: Low-dose oxymorphone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oxymorphone ER (10-20 mg q12h)
Trial: 15703368
Drug: Rifampin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin (2 x 300 mg q24h)
Trial: 15703368
Drug: Naltrexone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (50 mg q24h)
Trial: 12369078
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for acute myocardial infarction
Trial: 10064246
Drug: Itraconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole (200 mg/d for 12 months)
Trial: 10064246
Drug: Fluconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (200 mg/d for 12 months)
Trial: 6105519
Drug: Prednisone 20
RxNorm normalized name: prednisone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 20 mg daily
Trial: 6622929
Drug: Azathioprine 100
RxNorm normalized name: azathioprine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine 100 mg daily
Trial: 6105519
Drug: Prednisone 20
RxNorm normalized name: prednisone 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 20 mg and azathioprine 50 mg daily
Trial: 6105519
Drug: B vitamins
RxNorm normalized name: B-50 Hi Potency B Vitamins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B vitamins 2 tablets daily
Trial: 29691625
Drug: Minimally invasive
RxNorm normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Trial: 20181334
Drug: Brief information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief information about pre-endoscopy preparation (control group)
Trial: 12091194
Drug: Pharmacotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy with lithium and adjunctive psychotherapy specific to bipolar disorder
Trial: 12091194
Drug: Pharmacotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy with lithium and nonspecific intensive clinical management
Trial: 8942490
Drug: Standard-dose triptorelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose triptorelin for 8 weeks followed by reduced-dose triptorelin (100, 20, or 5 micrograms) until week 26
Trial: 8942490
Drug: Reduced-dose triptorelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-dose triptorelin (100, 20, or 5 micrograms)
Trial: 8942490
Drug: High-dose triptorelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose triptorelin
Trial: 8942490
Drug: Reduced-dose triptorelin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-dose triptorelin
Trial: 1959366
Drug: Pharmacokinetic dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacokinetic dosing of aminoglycosides
Trial: 25193506
Drug: 150 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/day ranitidine
Trial: 25193506
Drug: 300 mg/day
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/day ranitidine
Trial: 20874458
Drug: Mometasone furoate/formoterol
RxNorm normalized name: mometasone furoate/formoterol fumarate 100/5 MCG/INHAL Metered Dose Inhaler, 60 Actuations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone furoate/formoterol (MF/F) 200/10 μg
Trial: 20874458
Drug: Fluticasone propionate/salmeterol
RxNorm normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate/salmeterol (FP/S) 250/50 μg
Trial: 20874458
Drug: Mometasone furoate/formoterol
RxNorm normalized name: mometasone furoate/formoterol fumarate 100/5 MCG/INHAL Metered Dose Inhaler, 60 Actuations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mometasone furoate/formoterol (MF/F) 400/10 μg
Trial: 20874458
Drug: Fluticasone propionate/salmeterol
RxNorm normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate/salmeterol (FP/S) 500/50 μg
Trial: 18688066
Drug: Double-dose sirolimus-eluting
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Double-dose sirolimus-eluting stents (SES) (280 microg/cm2)
Trial: 18688066
Drug: Single-dose sirolimus-eluting
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single-dose sirolimus-eluting stents (SES) (140 microg/cm2)
Trial: 11220982
Drug: Sildenafil 10
RxNorm normalized name: sildenafil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 10 mg
Trial: 9973007
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg digoxin
Trial: 9973007
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg diltiazem‐CD
Trial: 9973007
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg digoxin + 240 mg diltiazem‐CD
Trial: 9973007
Drug: 0.25 mg
RxNorm normalized name: biotin 0.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg digoxin + 50 mg atenolol
Trial: 8475955
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of aspirin
Trial: 2183591
Drug: Golytely (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golytely (standard polyethylene glycol-based lavage solution)